SUBSCRIBE
SUBSCRIBE
News   Drug Development

Ark Therapeutics’ Phase III Brain Cancer Drug Trial Cleared To Continue Update

January 5, 2007 | 
1 min read

LONDON (AFX) - Ark Therapeutics Group PLC’s final-stage trial of an experimental drug to treat brain cancer has been cleared to continue without modification, by Europe’s medicine safety board.

Clinical research Phase III Regulatory Europe
MORE ON THIS TOPIC
Cardiovascular disease
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
April 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Climb up, hand help businessman build ladder
Diabetes
Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option
March 31, 2025
 · 
4 min read
 · 
Annalee Armstrong
FDA
Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down
March 31, 2025
 · 
3 min read
 · 
Heather McKenzie
World heart day. Sketch style human heart. Retro halftone hands reaching out to each other. Modern collage. Valentines day banner. Healthcare medical concept. Healthy lifestyle.
Cardiovascular disease
Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%
March 31, 2025
 · 
2 min read
 · 
Tristan Manalac